Identifying patient subgroups in MASLD and MASH-associated fibrosis: molecular profiles and implications for drug development

Abstract The incidence of MASLD and Wooden Bus MASH-associated fibrosis is rapidly increasing worldwide.Drug therapy is hampered by large patient variability and partial representation of human MASH fibrosis in preclinical models.Here, we investigated the mechanisms underlying patient heterogeneity using a discovery dataset and validated in distinc

read more